Wall Street Piles Into UnitedHealth: Argus Upgrades to Buy as Three More Firms Raise Targets After Q1 Crushes Expectations

• UnitedHealth’s Q1 2026 earnings beat and improved medical cost ratio have won backing from four major firms, though regulatory risks around Medicare Advantage remain a watch point for investors.

• UnitedHealth’s disciplined pricing strategy and exit from unprofitable Medicare Advantage markets are demonstrating that its turnaround is underway, though regulatory visibility around Medicare Advantage Stars ratings remains an open question.

• The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE.

UnitedHealth Group (NYSE:UNH) just earned a strong endorsement from four Wall Street firms following a better-than-expected Q1 2026 earnings report. Argus stepped up with the most significant action, upgrading UnitedHealth stock to Buy from Hold with a $400 price target, while three other firms raised their targets. For long-term investors watching this turnaround story, a rating change carries more signal than a target tweak.

If you’ve been following today’s price action, UnitedHealth Surges 8%, Humana Gains 4% as Earnings Strength Eases Medicare Advantage Concerns covers the sector-wide move. Here, we’re focused on what four analyst firms are saying and why their divergence on price targets matters.

Argus says UnitedHealth reported a “strong” Q1 as it pursues higher margins in its insurance lines, and the firm believes UnitedHealth is implementing disciplined pricing and exiting unprofitable Medicare Advantage markets. Argus isn’t just raising a number; it’s changing its fundamental view of the company’s trajectory.

READ: The analyst who called NVIDIA in 2010 just named his top 10 AI stocks

Morgan Stanley analyst Erin Wright raised her UNH stock price target to $395 from $375, arguing that with upside on key performance indicators and a “surprise” FY26 EPS guidance raise, UnitedHealth “showcased that its turnaround is underway.” That’s a confident statement from one of Wall Street’s most-watched healthcare analysts.

Oppenheimer lifted its UNH stock price target to $405 from $385, the highest of the four, noting that early 2026 trends in all segments, including Medicare Advantage and OptumHealth, were better than expectations. BofA took the most measured tone, raising its target to $371 from $337 while keeping a Neutral rating, calling guidance “conservative” on a 50-cent EPS raise after a 70-cent EPS beat and saying it’s awaiting further visibility on Stars ratings and the 2028 Medicare Advantage rate notice.